People · Operator
Named in public records as an officer, director or promoter · active 2016–2025 · Pharma, Pharmaceuticals, Other, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Bluejay Therapeutics, Inc. | — | Pharma | Series D+ | $221.7M | $2.1B | 2022 |
| Werewolf Therapeutics, Inc. | — | Pharmaceuticals | Series C | $128.2M | $2.1B | 2019 |
| Reunion Neuroscience, Inc. | — | Pharmaceuticals | Series D+ | $119.8M | $1.5B | 2024 |
| Oncorus, Inc. | — | Other | Series C | $115.1M | $921.8M | 2016 |
| Keros Therapeutics, Inc. | — | Biotechnology | Series C | $78.5M | $2.3B | 2020 |
| Crossbow Therapeutics, Inc. | — | Biotechnology | Series B | $67.8M | $128.2M | 2025 |
| Entact Bio, Inc. | — | Biotechnology | Series C | $40.3M | $426.8M | 2024 |
Alon Lazarus at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Alon Lazarus on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Briggs Morrison | 4 | 8 |
| Luke Evnin | 2 | 12 |
| Sakae Asanuma | 2 | 6 |
| Carl Gordon | 1 | 24 |
| Todd Foley | 1 | 12 |
| Cameron Wheeler | 1 | 9 |
| Christoph Westphal | 1 | 8 |
| Alexandra Cantley | 1 | 8 |
| Ansbert Gadicke | 1 | 7 |
| Richard Gaster | 1 | 7 |
| Derek DiRocco | 1 | 7 |
| Michael Ehlers | 1 | 6 |
| David Cordo | 1 | 6 |
| Robert Alexander | 1 | 6 |
| Edward Smith | 1 | 5 |
| Julius Knowles | 1 | 5 |
| Gregory Mayes | 1 | 5 |
| Andrew Sinclair | 1 | 5 |
| Nancy Hong | 1 | 4 |
| Daniel Hicklin | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.